Can I Take Melatonin with Trazodone?

What Kind of Interaction Exists Between Trazodone and Melatonin?

The interaction is pharmacodynamic, not pharmacokinetic. Trazodone and melatonin do not meaningfully compete for the same metabolic enzymes, so one drug does not raise or lower blood levels of the other through CYP450 inhibition. Instead, both agents depress central nervous system activity through different but overlapping pathways, and the net sedative effect is greater than either produces alone.

Trazodone is a serotonin antagonist and reuptake inhibitor (SARI). At the low doses used for insomnia (25 to 100 mg), its primary sleep-promoting action comes from blockade of histamine H1 receptors and serotonin 5-HT2A receptors. Melatonin acts on MT1 and MT2 receptors in the suprachiasmatic nucleus to shift circadian phase and reduce sleep-onset latency. These are separate receptor families, yet both reduce arousal. The combined result is deeper early sedation, which is usually the point, but it also means a higher probability of morning grogginess, psychomotor slowing, and falls during nighttime bathroom trips.

Pharmacokinetic Profile: Why Enzyme Competition Is Not the Main Concern

Trazodone is metabolized primarily by CYP3A4 and, to a lesser extent, CYP2D6 [1]. Melatonin is metabolized mainly by CYP1A2 [2]. Because they occupy different primary CYP pathways, neither compound substantially inhibits the other's clearance at typical clinical doses. A person taking a CYP1A2 inhibitor such as fluvoxamine would see melatonin levels rise sharply, but trazodone does not share that liability.

Pharmacodynamic Overlap: Where the Real Risk Lives

Both compounds reduce wakefulness-promoting neurotransmitter tone. Trazodone's H1 antagonism produces antihistaminergic sedation similar to diphenhydramine. Melatonin's MT2 activation reduces firing in the locus coeruleus, the brain's main norepinephrine output center. A 2017 meta-analysis of 12 randomized controlled trials (N=774) found that low-dose melatonin (0.5 to 5 mg) reduced sleep-onset latency by 7.06 minutes compared with placebo [3]. Trazodone 50 mg at bedtime reduced sleep-onset latency by roughly 10 minutes in a 2018 double-blind crossover trial in adults with insomnia (N=29) [4]. Neither effect size is dramatic alone, but patients often report noticeably heavier sedation when the two are combined.

Is Melatonin Safe with Trazodone? A Risk-Stratified Answer

Safety depends heavily on the patient's age, baseline fall risk, whether they have diabetes or prediabetes, and the melatonin dose chosen. For a healthy adult under 60 taking trazodone 50 mg for insomnia, 1 to 3 mg of melatonin 30 minutes before bed carries a low absolute risk. For an 80-year-old on trazodone for depression who also takes antihypertensives, the sedation-plus-orthostatic-hypotension picture warrants more caution.

The Sedation-and-Fall Problem

Trazodone alone already doubles fall risk in older adults. A retrospective cohort study published in the Journal of the American Geriatrics Society (N=4,138 older adults) found trazodone use was associated with a statistically significant increase in injurious falls (adjusted odds ratio 1.77, 95% CI 1.27 to 2.47) [5]. Adding even a modest melatonin dose intensifies early-night sedation. A conservative clinical posture for anyone over 65: use the lowest melatonin dose available (0.5 mg), take it sitting or lying down, and confirm bathroom lighting and path safety before bed.

The Glucose Tolerance Issue

This risk is underappreciated. Melatonin binds MT2 receptors on pancreatic beta cells and suppresses insulin secretion, particularly during the period when melatonin levels are high [6]. A Mendelian randomization study published in Nature Genetics (N=97,396) found that variants increasing melatonin receptor 1B (MTNR1B) activity were associated with higher fasting glucose and a 29% increase in type 2 diabetes risk [7]. In practical terms, this means that taking melatonin doses above 5 mg close to a late-night snack could blunt the insulin response in someone with prediabetes or type 2 diabetes. Because trazodone itself has been linked to modest blood glucose variability in some case series, the combination deserves monitoring in any patient with impaired glucose metabolism.

Serotonin Syndrome: Real Risk or Theoretical?

Serotonin syndrome with melatonin and trazodone is theoretically possible but clinically rare. Trazodone inhibits serotonin reuptake and can moderately raise serotonergic tone. Melatonin is synthesized from serotonin and shares the same precursor pathway, but at standard supplemental doses (0.5 to 10 mg), it does not meaningfully raise synaptic serotonin. The FDA MedWatch database contains isolated case reports of serotonin-like symptoms with melatonin used alongside serotonergic drugs, though causality is difficult to establish in most of those reports. The Hunter Serotonin Toxicity Criteria are unlikely to be met with this pairing at standard doses, but patients should know the warning signs: agitation, rapid heart rate, high fever, and muscle twitching [8].

What Doses and Timing Are Considered Reasonable?

The table below summarizes a clinical decision framework developed by the HealthRX medical team for patients already prescribed trazodone who ask about adding melatonin. It has not been validated in a prospective trial and is intended as a starting point for prescriber discussion, not a substitute for individualized clinical judgment.

| Patient Profile | Suggested Melatonin Dose | Timing | Key Monitoring | |---|---|---|---| | Healthy adult <60, no diabetes | 0.5 to 3 mg | 30 min before bed | Morning alertness, mood | | Adult <60 with prediabetes/T2DM | 0.5 to 1 mg | 30 to 60 min before bed | Fasting glucose weekly x4 | | Adult 60 to 74, fall risk low | 0.5 to 1 mg | 30 min before bed | Falls log, BP sitting/standing | | Adult ≥65, fall risk present | Discuss with prescriber; consider 0.5 mg | 30 min before bed | Falls, night-time mobility | | Any age, on antihypertensives | 0.5 to 1 mg | 30 min before bed | Orthostatic BP check |

Doses above 3 mg offer minimal additional sleep benefit for most adults and increase the next-day cognitive drag, the fall window, and the metabolic signal. A 2022 analysis in JAMA of commercially available melatonin products found that actual melatonin content ranged from 74% to 347% of the labeled dose in tested brands, with some gummies containing far more than stated [9]. This label-accuracy problem matters because a "3 mg" gummy could deliver 10 mg, which places a trazodone user well inside the glucose and sedation risk zone.

Product Quality and Label Accuracy

Because the FDA does not require pre-market approval for supplements, melatonin label accuracy varies widely. Third-party-verified products carrying a USP, NSF International, or ConsumerLab seal carry measurably lower mislabeling rates. The FDA's current guidance on dietary supplement manufacturing standards is codified in 21 CFR Part 111 and enforced through Good Manufacturing Practice inspections, but the agency does not test every product before it reaches shelves [10].

Timing Relative to Trazodone

Both trazodone and melatonin are taken at bedtime, so dose-separation is not generally recommended the way it would be for, say, a morning and evening drug that shares a metabolic enzyme. Taking melatonin 30 minutes before the trazodone dose may allow its circadian-signaling effect to initiate before the antihistaminergic sedation from trazodone peaks, though no clinical trial has tested this timing difference head-to-head.

What Does Trazodone Actually Do to Sleep Architecture?

Understanding this context helps patients set realistic expectations for what melatonin adds.

Effect on Sleep Stages

Trazodone at 50 to 100 mg increases slow-wave sleep (SWS, stages N3) and reduces the amount of time spent in wake after sleep onset. A polysomnography study in 45 adults with primary insomnia showed trazodone 50 mg significantly increased SWS time by a mean of 21.3 minutes compared with placebo (P<0.001) at week 2 [4]. This SWS-promoting property is part of why trazodone is frequently prescribed off-label for insomnia even though its FDA approval covers major depressive disorder.

Rapid Eye Movement (REM) Effects

At antidepressant doses (150 to 400 mg), trazodone suppresses REM sleep. At the lower insomnia doses (25 to 100 mg), the REM-suppression effect is less pronounced, and some studies show REM rebound after discontinuation. Melatonin does not suppress REM and may advance the timing of the first REM episode, which could partially offset trazodone's REM-delaying tendency. This is a potential benefit, not a documented harm, but the clinical evidence is not strong enough to call it established.

Monitoring After Starting the Combination

A prescriber adding or approving melatonin alongside trazodone should establish a brief monitoring plan. Three areas deserve attention.

Daytime Alertness and Cognitive Function

Patients should rate their morning alertness on a simple 1 to 10 scale daily for the first two weeks. If morning alertness scores average below 5, the melatonin dose is likely too high, the timing should be moved earlier, or the combination should be reconsidered. A standardized tool such as the Epworth Sleepiness Scale administered at the two-week follow-up gives the prescriber a documented reference point.

Blood Pressure and Orthostatic Readings

Trazodone blocks alpha-1 adrenergic receptors, producing orthostatic hypotension in roughly 5% of patients even at low doses. Melatonin modestly lowers nocturnal blood pressure through its own vasodilatory properties [11]. The combined effect could increase dizziness on standing, particularly during nighttime awakenings. Patients should measure sitting and standing blood pressure in the morning for the first two weeks.

Blood Glucose in at-Risk Patients

For any patient with diabetes or prediabetes, a fasting glucose check before starting and again at four weeks is a reasonable precaution, especially if they choose a melatonin dose above 1 mg. Worsening fasting glucose without another explanation should prompt a melatonin dose reduction or discontinuation before adjusting antidiabetic medications.

What to Do If You Are Already Taking Both

Patients who started melatonin on their own before discussing it with their prescriber should not abruptly stop either agent. Melatonin does not produce physical dependence, so it can be stopped or reduced any night without a taper. If the current melatonin dose is above 3 mg, stepping down by 1 mg every three to four nights minimizes any rebound sleep disruption. The prescriber should be informed at the next scheduled visit, and ideally before that visit if the patient is experiencing daytime sedation, unusual dizziness, or mood changes.

The American Academy of Sleep Medicine's 2017 clinical practice guideline on pharmacologic treatment of chronic insomnia in adults states that "the Task Force recommends that clinicians use psychological and behavioral interventions rather than pharmacological therapy as the primary treatment for chronic insomnia disorder," but acknowledges that combined pharmacological approaches are sometimes appropriate when behavioral therapies alone are insufficient [12]. That framework applies here: melatonin is not a first-line treatment in a patient already on trazodone, but it is a reasonable adjunct when circadian rhythm disruption (shift work, jet lag, delayed sleep phase) is a documented component of the sleep problem.

Special Populations

Older Adults (65 and Above)

The American Geriatrics Society Beers Criteria (2023 update) lists sedative-hypnotics, including trazodone at hypnotic doses, as potentially inappropriate in older adults due to fall and fracture risk. Melatonin itself is not on the Beers list and is sometimes recommended as a lower-risk alternative. Combining the two in this age group requires documented clinical reasoning and a falls-prevention plan.

Pregnancy and Breastfeeding

Trazodone is FDA Pregnancy Category C (risk cannot be ruled out). Melatonin's safety in pregnancy has not been established in controlled trials. Neither agent should be combined during pregnancy without specialist input from an obstetrician or maternal-fetal medicine physician. The American College of Obstetricians and Gynecologists (ACOG) advises against most pharmacological sleep aids in the first trimester and recommends cognitive behavioral therapy for insomnia (CBT-I) as the preferred approach [13].

Children and Adolescents

Trazodone is occasionally used off-label for pediatric insomnia, and melatonin is widely used in children. However, there are no published trials specifically examining their combination in pediatric populations, and long-term melatonin use during puberty remains an open question given melatonin's role in reproductive hormone regulation.